Diagnostic Radiopharmaceutical Trial Design: Is It Time to Change Nomenclature?

> “What’s in a name? That which we call a rose by any other name would smell as sweet…” > > — William Shakespeare The field of nuclear medicine is going through a renaissance with significant investment by a biotechnology and pharmaceutical industry finally recognizing the benefits of

Authors

Rodney J. Hicks (ORCID: https://orcid.org/0000-0002-0758-0824)

Institutions

St Vincent's Hospital Melbourne (AU)

Publication Details

Journal: Journal of Nuclear Medicine
Published: 2025-04-03
DOI: https://doi.org/10.2967/jnumed.125.269496
Primary Topic: Peptidase Inhibition and Analysis
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Diagnostic Radiopharmaceutical Trial Design: Is It Time to Change Nomenclature?

Rodney J. Hicks

Apr 3, 2025

Journal of Nuclear Medicine

Peptidase Inhibition and Analysis

article

Diagnostic Radiopharmaceutical Trial Design: Is It Time to Change Nomenclature?

Rodney J. Hicks

April 3, 2025article en

Abstract

Journal of Nuclear MedicineVol. 66(6)

St Vincent's Hospital Melbourne (AU)

Zero hunger

Openalex Percentile: Top 90%

Peptidase Inhibition and Analysis

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Diagnostic Radiopharmaceutical Trial Design: Is It Time to Change Nomenclature? — Rodney J. Hicks · Journal of Nuclear Medicine (2025) | TGRS Research Map | TGRS